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ABSTRACT
The neural mechanisms mediating one-trial and multi-trial behavioral
sensitization during early ontogeny are poorly understood. The purpose of this
thesis was to assess the importance of D2-like receptors for the induction of
cocaine- and methamphetamine-induced one-trial and multi-trial behavioral
sensitization during the middle and late preweanling period. In a series of four
experiments, rats were injected with saline or the selective dopamine D2-like
receptor antagonist raclopride 15 min prior to treatment with the indirect
dopamine agonists cocaine or methamphetamine. Acute control groups
received two injections of saline. The pretreatment regimens occurred on
either PND 16 or PND 20 (one-trial behavioral sensitization) or PND 13-16 or
PND 17-20 (multi-trial behavioral sensitization). On PND 17 or PND 21, rats
were challenged with either cocaine or methamphetamine and sensitized
responding was assessed. With only a single exception, both one-trial and
multi-trial cocaine- and methamphetamine-induced sensitization was evident
on PND 17 and PND 21. Importantly, the D2-like receptor antagonist
raclopride did not prevent the induction of cocaine- or
methamphetamine-induced one-trial behavioral sensitization. In regards to
multi-trial behavioral sensitization, raclopride failed to inhibit cocaine-induced
sensitized responding on PND 17 and PND 21. Interestingly, higher doses of
raclopride (0.5 and 1 mg/kg) were able to prevent the induction of multi-trial
methamphetamine-induced sensitization on PND 17. Therefore, D2-like
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receptor antagonism differentially affected methamphetamine-induced
behavioral sensitization depending on whether a one-trial or multi-trial
paradigm was employed. When considered together, these results suggest
that the neural mechanisms underlying the methamphetamine-induced
behavioral sensitization of preweanling rats differs depending on the type of
experimental paradigm (one- vs multi-trial) being used. Other potential
explanations (i.e., nonspecific antagonist effects, impact of contextual
conditioning, etc.) for this interesting effect are presented in the Discussion.
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CHAPTER ONE:
HUMAN MODELS OF ADDICTION
Psychostimulants have addictive properties that can induce complex
effects on human behavior. Taking into account the increasing rate of
psychostimulant use, psychostimulant addiction has become a profound
public health concern (Sax & Strakowski, 2001). One of the most frequently
used models to study the underlying mechanisms of drug addiction is
behavioral sensitization. Behavioral sensitization is characterized by a
progressive increase in behavioral responsiveness as a result of repeated
exposures to a psychostimulant drug (Kalivas & Stewart, 1991; Robinson &
Becker 1986; Sax & Strakowski, 2001; Strakowski & Sax, 1998). Figure 1
compares the typical pattern of drug-taking in human addicts with a model of
behavioral sensitization in animals.
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Figure 1. Comparison between Human Psychostimulant-induced Psychosis
and an Experimental Model of Behavioral Sensitization in Rats. The Addiction
Phase can Progressively Lead to Sensitization in Psychostimulant-induced
Psychosis. In Rats, Repeated Exposure to Psychostimulants can Lead to
Heightened Motor Activity. Adapted from Pierce and Kalivas (1997).

Although most behavioral sensitization studies are based on animal
models, recent evidence in the clinical literature has shown a role for
sensitization in human drug-seeking (Strakowski & Sax, 1998). For instance,
Strakowski, Sax, Setters, and Keck (1996) reported that volunteers with no
prior substance abuse history showed a progressive increase in energy,
mood, speech, and eye-blink rates when repeatedly treated with
amphetamine (0.25 mg/kg) twice daily over a span of four days. In another
study, participants showed a progressive increase in eye-blink rates and
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motor activity after receiving a single oral dose of amphetamine (0.25 mg/kg)
for six days (Strakowski & Sax, 1998). These data indicate that behavioral
sensitization occurs in humans and that the phenomenon may play a role in
drug addiction.
While numerous studies have examined the sensitizing effects of
psychostimulants in animal and human models, less focus has been paid to
the underlying neurobiological processes responsible for behavioral
sensitization. Dopamine plays a key role in mediating the stimulatory
properties of psychostimulants. Therefore, it is not surprising that dopamine
receptor systems have been linked to the induction (i.e., development) and
expression of psychostimulant-induced behavioral sensitization (Kuribara &
Uchihashi, 1993; Vezina & Stewart, 1989). The induction of behavioral
sensitization appears to be due to transient changes in neural functioning,
while the expression of sensitization is associated with enduring changes in
cellular function during withdrawal (Kalivas & Stewart, 1991).
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CHAPTER TWO:
DOPAMINE PHARMACOLOGY
Introduction
Catecholamine neurotransmitters are notable for their core chemical
structure referred to as the catehol (McTavish, Cowen, & Sharp, 1999).
Dopamine is one of the predominant catecholamine neurotransmitters in the
central nervous system (Ho & Loh, 1972). It is involved in a variety of
functions, such as motor activity, cognition, and hormone secretion (Jaber,
Robinson, Missale, & Caron, 1996).
In 1910, George Barger and James Ewens were the first to synthesize
dopamine. With the progression of research, dopamine was discovered to be
a neurotransmitter in the late 1950s. This was achieved when
spectrophoto-fluorometric techniques revealed significantly higher
concentrations of dopamine in the caudate nucleus than norepinephrine
(Carlsson, Lindqvist, Magnusson, & Waldeck, 1958). The dopaminergic
system was further explored by Dahlstrom and Fuxe (1965), who discovered
dopamine-containing pathways and their associated projections to various
areas of the forebrain.
Dopamine Projection Pathways
Dopaminergic neurons mediate gross and fine motor movements, as
well as reinforcement and planning (Ando, Johanson, Seiden, & Schuster,
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1985). Areas of the brain that have particularly high dopamine concentrations
include the substantia nigra pars compacta, hypothalamus, and ventral
tegmental area (Geffen, Jessell, Cuello & Iversen, 1976; Palkovits,
Brownstein, Saavedra, & Axelrod, 1974). These specific brain regions give
origin to three major dopamine projection pathways. The nigrostriatal pathway,
which modulates motor activity, begins at the substantia nigra and projects to
the basal ganglia (Geffen et al., 1976; Huang, Zhou, Chase, Gusella, Aronin,
& DiFiglia, 1992). Interestingly, degeneration of nigral neurons, which make up
the nigrostriatal pathway, contributes to the progression of Parkinson’s
disease (Damier, Hirsch, Agid, & Graybiel, 1999). The mesolimbic pathway
originates in the ventral tegmental area and projects to the nucleus
accumbens (i.e., ventral striatum). These brain areas mediate reward and play
a key role in addictive behaviors (Chang & Kitai, 1985). Lastly, the
mesocortical pathway originates in the ventral tegmental area and projects to
the prefrontal cortex (Carr & Sesack, 2000; Lewis & O’Donell, 2000). This
pathway contributes to higher-level cognitive functions and planning
(Seamans, Floresco, & Phillips, 1998).
Synthesis of Dopamine
Synthesis of dopamine occurs in several biochemical steps (Nagatsu,
Levitt, & Udenfriend, 1964). The process is initiated when tyrosine is catalyzed
by tyrosine hydroxylase (TH) and produces dihydroxyphenylalanine (L-DOPA)
(Nagatsu, Levitt, & Udenfriend, 1964; Smidt, Smits, & Burbach, 2003).
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Dopamine is made when L-DOPA is further catalyzed by the enzyme aromatic
amino acid decarboxylase (AADC) (Roth, 1979; Sourkes, 1979). The rate of
dopamine synthesis is determined by the activity of tyrosine hyrdroxylase (i.e.
the rate-limiting step). Production of dopamine occurs in the presynaptic
terminals of dopaminergic neurons, after which the neurotransmitter is
packaged into synaptic vesicles. Dopamine is then released via
calcium-dependent exocytosis (Binder, Kinkead, Owens, & Nemeroff, 2001).
Dopamine Receptors: D1-Like and D2-Like
The classification of dopamine receptors is based on their interaction
with G-coupled protein complexes. There are a total of five dopamine receptor
subtypes that can be categorized into two populations of dopamine receptors,
namely D1-like and D2-like receptors. Based on similarities in
pharmacological actions and structure, the D1-like family is made up of D1
and D5 receptors; whereas, the D2-like family consists of the D2, D3, and D4
receptors (Jaber et al., 1996).
In regards to pharmacological actions, D1-like receptors are coupled
with Gs complexes. When activated, these Gs complexes stimulate the activity
of adenylyl cyclase and increase the production of cyclic AMP. In contrast,
D2-like receptors are coupled with Gi complexes and inhibit the activation of
adenylyl cyclase (Kebabian, Beaulieu, & Itoh, 1984). The disparate actions of
D1-like and D2-like receptors are described in pharmacological studies using
agonists and antagonists. For example, Roberts-Lewis et al. (1986) provided
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evidence that D1-like receptors are positively coupled with adenylyl cyclase
activity by measuring dopamine release after SKF38393 or amphetamine
treatment. The inhibitory relationship between adenylyl cyclase activity and
D2-like receptors was discovered by applying vasoactive intestinal peptide in
the anterior pituitary gland (Onali, Schwartz, & Costa, 1981).
Dopamine Receptor Distribution in the Brain
D1-Like Receptors
The D1 receptor subtype is the most widespread and highly
concentrated dopamine receptor in the brain (Boyson, McGonigle, & Molinoff,
1986). A technique called in-situ hybridization is commonly used to examine
gene expression in individual cells (Langdale, 1994). In regards to distribution
of dopamine receptors in the brain, in-situ hybridization studies have shown
that dopamine D1 receptors are primarily localized in the striatum, nucleus
accumbens, and olfactory tuburcle, whereas cells expressing D 1 receptor
mRNA are located in the thalamus, hypothalamus, and limbic system
(Fremeau, Duncan, Fornaretto, Dearry, Gingrich, Breese, & Caron, 1991).
Other techniques, such as autoradiography, have also been used to localize
dopamine receptor sites. For example, Boyson et al. (1986) examined the
distribution of dopamine receptors by using the D1-like radioligand SCH
23390. Results showed that D1 receptors were present throughout the
forebrain, with the highest densities occurring in the substantia nigra, nucleus
accumbens, olfactory tubercle, and striatum (Boyson et al., 1986).
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Although difficult to examine due to the lack of selective ligands, D5
receptor mRNA is expressed in striatum, cerebral cortex, lateral thalamus,
medial thalamus, and hippocampus (Choi, Machida, & Ronnekleiv, 1995;
Meador-Woodruff, Mansour, Grandy, Damask, Civelli, & Watson, 1992).
D2-Like Receptors
D2 receptors are found in lower quantities than D1 receptors (Boyson et
al., 1986). In-situ hybridization revealed that D2 receptor mRNA was found in
the ventral tegmental area, nucleus accumbens, olfactory tubercle, and
substantia nigra as well as in other dopamine projection fields
(Meador-Woodruff, Mansour, Bunzow, Van Tol, Watson, & Civelli, 1989).
Autoradiography studies also show that D2 receptors are found in high
densities in the olfactory bulb and lateral septum (Charuchinda, Supavilai,
Karobath, & Palacios, 1987).
The D3 receptor is expressed preferentially in the mesolimbic system,
but in lower quantities than D1 and D2 receptors (Richtand et al., 1995). While
D3 mRNA is found in the olfactory tubercle and nucleus accumbens,
especially high densities of D3 mRNA are expressed in the islands of Calleja
(Diaz, Levesque, Lammers, Griffon, Martres, Schwartz, & Sokoloff, 1995).
Distribution of the D4 receptor is unique, because D4 mRNA expression
is minuscule in striatal areas; whereas, D1, D2, D3, and D5 receptor mRNA is
abundant in the striatum. The D4 receptor subtype is mainly concentrated in
the hippocampus, lateral septal nucleus, entorhinal cortex, and medial
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preoptic area of the hypothalamus (Primus, Thurkauf, Xu, Yevich, McInerney,
Shaw, Tallman, & Gallager, 1997).
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CHAPTER THREE:
ONTOGENY OF THE DOPAMINE SYSTEM
Previous studies examining the dopamine system during postnatal
development have focused on age-dependent changes in dopamine levels
and the distribution of dopamine receptors across brain. Techniques such as
in-situ hybridization, autoradiography, as well as receptor binding are
commonly used to visualize and quantify ontogenetic changes in the
dopamine system.
As is true of adult rats, dopamine neurons in neonatal and preweanling
rats are predominantly found in the substantia nigra, ventral tegmental area,
and hypothalamus. These brain regions give rise to three main pathways (i.e.
the nigrostriatal, mesolimbic, and mesocortical pathways) that are present at
birth (Antonopoulos, Dori, Dinopoulos, Chiotelli, Parnavelas, 2002; Chang &
Kitai, 1985; Geffen, Jessell, Cuello, & Iversen, 1976; Lewis & O’Donell, 2000;
Olson & Seiger, 1972). Dopamine synthesis can be detected at birth, with
dopamine levels increasing linearly until approximately puberty, when adult
levels are reached (Olson & Seiger, 1972; Park, Kitahama, Geffard, & Maeda,
2000).
Postnatal Development: D1-Like and D2-Like Receptors
During the first three postnatal weeks, profound changes in the profile
of dopamine receptors take place. As mentioned previously, dopamine
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receptors are classified based on their interaction with G-coupled protein
complexes that either stimulate or inhibit adenylyl cyclase activity.
Autoradiography studies examining the development of dopamine receptors
indicate that D1-like receptors steadily increase in density from postnatal day
1 (PND 1) to around PND 28, when dopamine receptors have reached adult
levels (Murrin & Zeng, 1990; Rao, Molinoff, & Joyce, 1991; Zeng, Hyttel, &
Murrin, 1988). Other studies demonstrate a gradual increase in D1-like
receptors until approximately the onset of puberty (PND 40) when dopamine
receptors are over-expressed. The number of dopamine receptors then
decline (pruning), to levels that are maintained throughout adulthood
(Andersen, Thompson, Rutstein, Hostetter, & Teicher, 2000; Giorgi, DeMontis,
Porceddu, Mele, Calderini, Toffano, & Biggio, 1987).
D2-like receptors also progressively increase with age, and reach adult
levels around PND 21 (Hartley & Seeman 1983; Murrin & Zeng, 1986;
Schrambra, Duncan, Breese, Fornaretto, Caron, & Fremeau, 1994). Other
studies report a linear increase in D2-like receptors up to adolescence when
dopamine receptors are over-expressed, followed by a decline in receptors
that are maintained throughout adulthood (Andersen et al., 2000).
Dopamine Receptor Distribution During Postnatal Development
D1-Like Receptors
The D1 receptor subtype can be detected in the striatum and nucleus
accumbens at birth (Leslie, Robertson, Cutler, & Bennett, 1991; Zeng, Hyttel,
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& Murrin, 1988). In addition, D1 receptors are highly concentrated in the frontal
cortex as well as the entorhinal cortex during early postnatal development
(Tarazi & Baldessarini, 2000). Normal development of dopamine D 1 receptors
can be disrupted when neonatal pups are injected with the neurotoxin
6-hydroxydopamine, resulting in a decrease in D1 binding sites (Neal & Joyce,
1992).
Postnatal development of the D5 receptor can be detected in the
striatum, globus pallidus, frontal cortex, and cingulate cortex (Araki, Sims, &
Bhide, 2007). The developmental profile of D5 mRNA expression shows a
linear increase from PND 0 until PND 21, when they reach maximal levels
(Araki et al., 2007).
D2-Like Receptors
During early stages of development, the D2 receptor subtype is
generally found in higher quantities than the D1 receptor (Tarazi &
Baldessarini, 2000). More specifically, autoradiographic results show that D2
receptor densities in the striatum and nucleus accumbens are greater than
other dopamine receptor subtypes (Tarazi & Baldessarini, 2000).
The ontogenetic profile of the D3 receptor is characterized by an
increase in the number of binding sites across early postnatal development.
For example, Gurevich, Himes, and Joyce (1998) showed that D 3 mRNA
expression and D3 binding sites were detectable in low quantities at PND 7 in
both the nucleus accumbens and islands of Caleja. In these brain regions, D3
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receptors reached maximal levels at PND 14 and PND 90, respectively. As
with adults, the D3 receptor subtype show that they are preferentially localized
in the islands of Calleja (Diaz et al., 1995; Levesque, Diaz, Pilon, Martres,
Giros, Souil, Schott, Morgat, Schwartz, & Sokoloff, 1992).
During early postnatal development, the D4 receptor subtype is present
in lower quantities than D1 and D2 receptors in the nucleus accumbens,
striatum, frontal cortex, and entorhinal cortex (Tarazi & Baldessarini, 2000).
Interestingly, D4 mRNA expression reaches maximal levels by PND 3. This
contrasts with the D2 receptor subtype, which does not reach maximal levels
until PND 28 or later (Andersen et al., 2000; Nair & Mishra, 1995).
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CHAPTER FOUR:
MECHANISM OF ACTION: INDIRECT DOPAMINE AGONISTS
Indirect dopamine agonists, such as cocaine and amphetamine,
increase extracellular monoamine concentrations. More specifically, cocaine
preferentially increases dopamine, norepinephrine, and serotonin levels,
whereas amphetamine increases dopamine and norepinephrine (Ritz, Lamb,
Goldberg, & Kuhar, 1987; Seiden, Sabol, & Ricaurte, 1993). In terms of
cocaine, monoamine concentrations are enhanced by blocking the reuptake of
newly released neurotransmitter from the synaptic cleft (Meyer & Quenzer,
2005). For example, using an in-vivo microdialysis technique, Reith, Li, and
Yan (1997) discovered that dialysate levels of all three amines were increased
in the ventral tegmental area following administration of cocaine (20 mg/kg).
Excitatory amino acids, such as glutamate, also play a role in the behavioral
effects of cocaine. Cocaine indirectly enhances glutamatergic
neurotransmission by activating these excitatory neurons, particularly in the
nucleus accumbens and ventral tegmental area (Kalivas & Duffy, 1998; Smith,
Mo, Guo, Kunko, & Robinson, 1995).
Amphetamine- and methamphetamine-like stimulants increase
monoamine concentrations by blocking reuptake transporters; however, unlike
cocaine, they also bind to monoamine transporters by acting as a false
substrate. The end result is that amphetamine and methamphetamine
promote reverse transport of cytosolic transmitter, thereby releasing
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monoamines from non-vesicular stores (Reith, Li, & Yan, 1997). Fumagalli,
Gainetdinov, Valenzano, and Caron (1998) reported an 18-fold increase in
extracellular dopamine levels in wild type mice that were subcutaneously
injected with methamphetamine (30 mg/kg). In the same study, DOPAC levels
were decreased by roughly 60% in both wild type and DAT knockout mice.
The latter finding shows that methamphetamine also increases dopamine
levels by inhibiting monoamine oxidase (MAO), which is an enzyme that
catabolizes dopamine (Fumagalli et al., 1998).
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CHAPTER FIVE:
ADULT SENSITIZATION: INDIRECT DOPAMINE AGONISTS
Indirect Dopamine Agonists: Adult Multi-Trial Sensitization
Behavioral sensitization occurs when an animal is repeatedly exposed
to various indirect dopamine agonists (e.g. cocaine, amphetamine, or
methamphetamine), and is then challenged with the same drug at a later time
point. This procedure results in an augmented locomotor response that can be
observed when the animal is tested one day to several months after
discontinuation of the drug (Kalivas & Stewart, 1991; Leith & Kuczenski, 1982;
McDougall et al., 2007; Robinson & Becker, 1986). Using this paradigm, adult
rats usually exhibit an enhanced locomotor response when challenged later
with an indirect dopamine agonist (Leith & Kuczenski, 1982).
Indirect dopamine agonists are able to produce short- and long-term
behavioral sensitization in adult rats. For example, sensitization occurs when
a short withdrawal interval is employed. In one case, rats receiving repeated
treatments of methamphetamine, followed by a five-day withdrawal period,
showed an enhanced behavioral response after a challenge injection of
methamphetamine (Laviola, Pascucci, & Pieretti, 2001). Sensitization is also
robust when a longer duration withdrawal period is used. Kolta, Shreve, De
Souza, and Uretsky (1985) showed enhanced locomotor activity after rats
were chronically treated with amphetamine and challenged 15 or 30 days
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later. This enhanced locomotion occurs in parallel with increased levels of
endogenous dopamine, which is evident after longer withdrawal periods.
Drug dose is a contributing factor to the sensitizing effects of
psychostimulants. More specifically, repetitive treatment with large doses of a
psychostimulant typically produces strong behavioral sensitization (Frantz,
O’Dell, & Parsons, 2007; Post & Rose, 1976). For example, repetitive
injections of a low dose of cocaine (10 mg/kg) across a five-day interval
produces increased locomotion with minute stereotypic movements (Frantz et
al., 2007). Davidson and colleagues (2002), however, observed a more robust
sensitized response, as well as intense stereotypy, when rats were repeatedly
given 40 mg/kg cocaine across a six-day interval (Davidson, Lazarus, Lee, &
Ellinwood, 2002).
Repeated administration of various doses of amphetamine can also
lead to sensitization. For instance, a low pretreatment dose of either 0.5 or
1 mg/kg amphetamine is enough to produce sensitization (Hall, Stanis, Avila,
& Gulley, 2008; Hooks, Jones, Neil, & Justice Jr., 1992). Higher doses of
amphetamine lead to focused stereotypy, such as sniffing and licking (Eichler,
Antelman, & Black, 1980). In regards to locomotion, Leith and Kuczenski
(1982) observed a multi-phasic response after repeated administration of
moderate to high doses of amphetamine (2 or 3 mg/kg) for six days. This
multi-phasic response is best represented by a U-shape curve, in which there
is a rapid onset of locomotor activity, a decrease in locomotion due to intense
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focused stereotypy, followed by a post increase in locomotor activity (Leith &
Kuczenski, 1982).
Repeated administration of methamphetamine also causes a
progressive increase in locomotor activity. For example, mice treated with
10 doses of 1, 2, or 4 mg/kg methamphetamine showed a progressive
enhancement in locomotor activity. In general, mice receiving 1 mg/kg
methamphetamine showed a slight increase in locomotor sensitization;
whereas, 4 mg/kg methamphetamine produced robust stereotypic behavior
(Hirabayashi & Alam, 1981).
During the conditioning phase, the nature of the drug-environment
pairings can affect the magnitude of the sensitized response. More
specifically, behavioral sensitization is more pronounced when the adult rat or
mouse is pretreated and tested in the same environment (i.e.
context-dependent sensitization) (Anagnostaras & Robinson, 1996; Battisti,
Chang, Uretsky, & Wallace, 1999; Drew & Glick, 1989; McDougall et al.,
2007). In contrast, behavioral sensitization is weaker in adult animals when
drug pretreatment and drug challenge occur in separate environments (i.e.
context-independent sensitization). (Laviola, Wood, Kuhn, Francis & Spear,
1995; McDougall, Cortez, Palmer, Herbert, Martinez, Charntikov, & Amodeo,
2009). For example, adult rats failed to express a sensitized response when
drug challenge occurred in a context that was never paired with the
pretreatment drug (Anagnostaras, Schallert, & Robinson, 2002).
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Indirect Dopamine Agonists: Adult One-Trial Sensitization
Although most studies examine behavioral sensitization using multi-trial
procedures, sensitization has also been observed in adult rats and mice after
a single pretreatment injection of a psychostimulant (McDougall, Reichel, Cyr,
Karper, Nazarian, & Crawford, 2005; Weiss, Post, Pert, Woodward, &
Murman, 1989). When a one trial procedure is used, sensitization is typically
measured soon after the pretreatment injection and within the same
environmental context (i.e., pretreatment and test injections occur in the test
chamber). For example, adult rats conditioned with 30 mg/kg cocaine showed
robust locomotor sensitization when challenged a day later with 10 mg/kg
cocaine (McDougall et al., 2007). Amphetamine-induced sensitization was
also observed in wild type and D1-defiecient mice after a one-day
pre-exposure phase (McDougall et al., 2005).
Environmental context is especially critical when adult rats and mice
are provided only a single exposure to a psychostimulant. For example, adult
mice displayed robust behavioral sensitization when conditioned with a high
dose of cocaine (40 mg/kg) and challenged one day later with a lower dose of
cocaine (10 mg/kg) in the same previously novel environment (Jackson &
Nutt, 1993). In contrast, adult rats and mice do not exhibit behavioral
sensitization when pretreatment and testing occur in different environments.
For example, adult male and female rats pretreated with cocaine in the home
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cage showed a lack of sensitized responding when injected with cocaine in
the testing chamber 24 hours later (McDougall et al., 2009).
The ability of psychostimulants to enhance locomotion and stereotopy
are dose-dependent. Increased locomotor activity is observed when the
animal is pretreated with a high dose of psychostimulant and is then
challenged with a lower dose (Battisti et al., 1999; Jackson et al., 1993;
McDougall et al., 2007; 2009). Stereotypy is preferentially observed when high
doses of psychostimulant are used. For example, Battisti and colleagues
showed that mice pretreated with 10 mg/kg amphetamine and challenged
48 hours later with 7 mg/kg amphetamine displayed robust stereotypic
behaviors (Battisti et al., 2009).
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CHAPTER SIX:
PREWEANLING SENSITIZATION: INDIRECT DOPAMINE AGONISTS
Indirect Dopamine Agonists in Preweanling Rats:
Multi-Trial Behavioral Sensitization
As is true with adult animals, young rats exhibit behavioral sensitization
when repeatedly exposed to psychostimulants (e.g. cocaine, amphetamine, or
methamphetamine) (Duke, O’Neil, & McDougall, 1997; McDougall, Duke,
Bolanos, & Crawford, 1994; Wood, Tirelli, Syder, Heyser, LaRocca, & Spear,
1998). Although qualitatively similar, behavioral sensitization differs between
young and adult animals. Some of the factors that differentially affect
behavioral sensitization in young and adult rats include duration of the
withdrawal period, the number of drug exposures, as well as the importance of
drug-environment pairings.
Indirect dopamine agonists produce long-term behavioral sensitization
in adult rats that can be detected for months after the last drug exposure
(Leith & Kuczenski, 1982; Robinson et al., 1982). In contrast, the longevity of
multi-trial behavioral sensitization in preweanling rats is much shorter. For
example, McDougall and colleagues (1994) examined the effects of
amphetamine-induced behavioral sensitization in the early preweanling period
and found that amphetamine produced short-term sensitization when using a
2-day interval, but long-term sensitization was not evident when an 8-day
treatment-to-test interval was employed (McDougall et al., 1994). In another
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case, however, long-term cocaine sensitization was evident during the late
preweanling period when testing occurred after 21 days of drug abstinence
(Snyder, Katovic, & Spear, 1998). Taken together, age-related neural changes
appear to affect the magnitude of the sensitized response after short or long
drug abstinence (Snyder et al., 1998).
In adult rats, the dose of psychostimulant used is a constraining
influence on the robustness of the sensitized response (Jackson & Nutt, 1993;
Weiss, Post, Pert, Woodward, & Muran, 1989). Similarly, drug dose impacts
pharmacological responsiveness during early ontogeny. For example,
cocaine-induced behavioral sensitization was more robust when medium
(15 mg/kg) to large doses (30 mg/kg) of cocaine were administered at
PND 21, with an adult-like pattern of locomotor activity being evident (Ujike,
Tsuchida, Akiyama, Fujiwara, & Kuroda, 1995). In addition, repeated
treatment with a moderate dose (2 mg/kg) of methamphetamine produces
robust behavioral sensitization in late preweanling age groups (Fujiwara,
Kazahaya, Nakashima, Sato, & Otsuki, 1987).
Environmental cues influence the sensitized responding of preweanling
rats when a multi-trial procedure is used. Specifically, the sensitized response
is more robust when pretreatment and testing occur in the same environment
(i.e. context-dependent sensitization); however, the sensitized response is
weaker or absent when pretreatment and testing occur in distinct
environments (i.e. context-independent sensitization). For example,

22

preweanling rats repeatedly treated with cocaine (5, 15, or 30 mg/kg) in a
novel context showed strong behavioral sensitization when tested in the same
previously novel environment (Wood et al., 1998). In contrast, preweanling
rats would only exhibit short-term behavioral sensitization, but not long-term
sensitization, when cocaine was repeatedly administered in the home cage
during the pretreatment phase (McDougall, Cortez, Palmer, Herbert, Martinez,
Charntikov, & Amodeo, 2009; Zavala, Nazarian, Crawford, & McDougall,
2000).
Indirect Dopamine Agonists in Preweanling Rats:
One-Trial Behavioral Sensitization
Like adults, preweanling rats exhibit a strong sensitized response after
being given a single exposure to a variety of indirect agonists (e.g. cocaine,
methamphetamine, and amphetamine) (Herbert, Der-Ghazarian, Palmer, &
McDougall, 2010; Kozanian, Gutierrez, Mohd-Yusof, & McDougall, 2012).
Adult rats only show one-trial behavioral sensitization when a
context-dependent procedure is used (Battisti, Uretsky, & Wallace, 2000;
McDougall, Baella, Stuebner, Halladay, & Crawford, 2007); whereas, young
rats show strong sensitized responding when pretreatment and testing occur
in distinct environments. For example, preweanling rats pretreated with
30 mg/kg cocaine showed robust context-independent sensitization when
challenged with 20 mg/kg cocaine on the test day (McDougall, Kozanian,
Greenfield, Horn, Gutierrez, & Mohd-Yusof, 2011). In another case, Kozanian
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et al. (2012) showed that young rats conditioned with 4 mg/kg
methamphetamine in the home cage exhibited strong context-independent
behavioral sensitization when challenged 24 hours later with 2 mg/kg
methamphetamine in the test chamber.
Previous research has also characterized the ontogenetic profile of
psychostimulant-induced one-trial behavioral sensitization. More specifically,
psychostimulants preferentially induce one-trial behavioral sensitization
depending on the age of the animal. For example, McDougall et al. (2011)
showed that cocaine produced robust one-trial behavioral sensitization when
young rats were pretreated on PND 19 and tested on PND 21, while various
dose combinations of methamphetamine and amphetamine did not produce
one-trial behavioral sensitization in this age group. In contrast, one-trial
cocaine-induced behavioral sensitization was not evident when younger
(PND 16-17) and older (PND 24-25) rats were tested. Methamphetamine, on
the other hand, was able to produce one-trial sensitization in younger age
groups (PND 12-13 or PND 16-17) (Kozanian et al., 2012). These
age-dependent differences in psychostimulant-induced effects could be due to
ontogenetic changes in the dopamine system (see “Ontogeny of the
Dopamine System” chapter).
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CHAPTER SEVEN:
NEURAL MECHANISMS UNDERLYING THE DEVELOPMENT
AND EXPRESSION OF BEHAVIORAL SENSITIZATION
Previous studies have employed selective D1-like and D2-like receptor
antagonists to assess the neural mechanisms responsible for the induction
(i.e. development) and expression of behavioral sensitization. Current theory
suggests that the induction of behavioral sensitization is due to transient
changes in neural function caused by repeated injections of the drug, while
expression of the sensitized response is associated with enduring changes in
cellular function during withdrawal (Kalivas & Stewart, 1991). D1-like and
D2-like receptors are thought to play an important role in these processes,
however, the relationship of these receptors to sensitization is complex.
Induction of Behavioral Sensitization
Role of Dopamine D1-Like Receptors
Researchers have suggested that stimulation of D1-like receptors,
particularly in the ventral tegmental area, is necessary for the induction of
amphetamine-induced behavioral sensitization (Vezina, 1996). Curiously, the
importance of D1-like receptors appears to vary depending on the
psychostimulant used. Specifically, D1-like receptor antagonists block the
induction of amphetamine-induced behavioral sensitization (Vezina & Stewart
1989). For example, rats repeatedly treated with SCH 23390 prior to
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methamphetamine administration for 14 days did not show locomotor
sensitization when tested after 3 months of drug abstinence (Hamamura,
Akiyama, Akimoto, Kashihara, Okumura, Ujike, & Otsuki, 1991). Likewise,
Ujike, Onoue, Akiyama, Hamamura, and Otsuki (1989) showed that rats
receiving daily administrations of SCH 23390 (0.5 mg/kg) in combination with
methamphetamine (4 mg/kg) for 14 days did not show elevated locomotor or
stereotypic behavior on the test day, thus indicating that SCH 23390 blocked
the induction of methamphetamine-induced sensitization.
In contrast, many studies have shown that SCH 23390 does not affect
the induction of cocaine-induced behavioral sensitization when using a
multi-trial paradigm (Kuribara & Uchihashi, 1993; Vezina & Stewart, 1989;
White, Joshi, Koeltzow, & Hu, 1998). However, Fontana and colleagues
(1993) reported that SCH 23390 was able to prevent the conditioned effects
of one-trial cocaine-induced sensitization. Thus, it appears that D1-like
receptor blockade differentially affects behavioral sensitization depending on
the psychosimulant being used. It is possible that cocaine and amphetamine
differentially affect compensatory mechanisms or redundant pathways
(Karper, De La Rosa, Newman, Krall, Nazarian, McDougall, & Crawford, 2002;
White et al., 1998). The discrepant findings reported by Fontana et al. (1993)
suggest that D1-like receptors are associated with conditioning effects rather
than reward; whether this factor may underlie the differences between cocaine
and amphetamine is uncertain.
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Role of Dopamine D2-Like Receptors
D2-like receptors also play a role in mediating behavioral sensitization.
For example, mice repeatedly treated with the D2-like antagonist haloperidol
(0.025, 0.1, 0.4 mg/kg), followed by methamphetamine, showed a
dose-dependent decrease in the strength of the sensitized response
(Kuribara, 1994). In the same manner, other studies found that haloperidol
was able to block the induction of cocaine-induced behavioral sensitization
(Mattingly, Rowlett, Ellison, & Rase, 1996; Weiss et al., 1989). Interestingly,
the D2-like receptor antagonist sulpiride was unable to block the induction of
cocaine sensitization (Mattingly, Hart, Lim, & Perkins, 1994). The disparate
actions of haloperidol and sulpiride could be due to their respective
mechanisms of action. For example, haloperidol not only binds to dopamine
receptor sites but, at high doses, binds to serotonin receptor sites (O’Dell, La
Hoste, Wildmark, Shapiro, Potkin, & Marshall, 1990). Hence, the ability of
haloperidol to block cocaine-induced sensitization may be related to its
combined actions on dopaminergic and non-dopaminergic systems (Mattingly
et al., 1995). Sulpiride also has great difficulty in crossing the blood-brain
barrier, so sulpiride’s lack of efficacy could be due to pharmacokinetic factors.
Although it is generally accepted that D2-like receptors are important
for the induction of behavioral sensitization, the brain areas where these
receptors are located is largely unknown. In 2002, Beyer and Steketee
reported that D2-like receptors in the medial prefrontal cortex are responsible
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for mediating the induction of behavioral sensitization; whereas, Jung and
colleagues (2013) showed that stimulation of D2-like receptors in the nucleus
accumbens is not involved the inductive process.
In summary, the role of D1-like and D2-like receptors in mediating the
induction of psychostimulant-induced behavioral sensitization is complex. For
example, while D1-like receptors play a prominent role in the induction of
amphetamine-induced sensitization, their importance for cocaine-induced
sensitization is much less critical. Likewise, D2-like receptor functioning
appears to be necessary for the induction of methamphetamine- and
cocaine-induced multi-trial sensitization, although studies involving sulpiride
provide inconsistent findings. Considering these disparate results, more
research is needed to determine the importance of dopamine receptors for the
induction of psychostimulant-induced behavioral sensitization.
Expression of Behavioral Sensitization
Role of D1-Like Receptors
Stimulation of D1-like receptors in the nucleus accumbens is required
for the expression of behavioral sensitization (Pierce & Kalivas, 1997). For
example, rats and mice treated with SCH 23390 on the test day displayed an
absence of cocaine or methamphetamine sensitization (Kuribara & Uchihashi,
1994; White et al., 1981). In another case, administering SCH 23390 prior to
cocaine at various intervals (Day 1, 17, 14, and 21) blocked the expression of
cocaine-induced behavioral sensitization (McCreary & Marsden, 1993).
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Role of D2-Like Receptors
While dopamine D2-like receptors are involved in the induction of
behavioral sensitization, these receptors are not necessary for the expression
of sensitization. For example, the D2-like antagonist pimozide is unable to
block the expression of amphetamine-induced sensitization (Beninger &
Hahn, 1983). Similarly, Beninger and Herz (1986) found that pimozide
(0.4 mg/kg) pretreatment failed to prevent the expression of cocaine-induced
behavioral sensitization in a context-specific environment.
In summary, repeated treatment with a psychostimulant can lead to
neurochemical alterations that are associated with the long-term expression of
behavioral sensitization. Although D1-like and D2-like receptors are intimately
involved in the induction of amphetamine-induced sensitization, only D1-like
receptors are necessary for expression.
Development of Sensitization in Young Rats
While numerous studies have focused on the role of dopamine
receptors for the induction and expression of behavioral sensitization in adult
rats and mice (Hamamura et al., 1991; Kuribara, 1994; Kuribara & Uchihashi,
1994; Vezina & Stewart, 1989), the role of dopamine receptors for the
ontogeny of behavioral sensitization has not been studied in detail. Recently,
however, one study did examine the importance of D1-like receptors for the
induction of psychostimulant-induced behavioral sensitization in preweanling
rats. Using a one-trial procedure, rat pups were pretreated with SCH 23390 at
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0, 15, 30, or 60 min before methamphetamine (2 mg/kg) or cocaine
(20 mg/kg) administration. At none of these time points did D1-like receptor
blockade disrupt sensitized responding. Thus, the inability of SCH 23390 to
impact methamphetamine- or cocaine-induced behavioral sensitization
suggests that D1-like receptor stimulation is unnecessary for behavioral
sensitization during the preweanling period (Mohd-Yusof, Gonzalez, Veliz, &
McDougall, 2014).
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CHAPTER EIGHT:
SUMMARY
Thesis Statement
Behavioral sensitization occurs when rats are repeatedly exposed to
various indirect dopamine agonists (e.g. cocaine, methamphetamine, or
amphetamine). In multi-trial behavioral sensitization paradigms, adult rats and
mice typically show robust “context-dependent” sensitization when drug
pretreatment and testing occur in the same novel environment.
“Context-independent” behavioral sensitization can also be observed in adults
when pretreatment and testing occurs in two separate and distinct
environments. Different patterns of results are observed in adult rats and mice
when using a one-trial procedure; adults only exhibit one-trial behavioral
sensitization if drug pretreatment and testing occur in the same previously
novel environment.
Preweanling rats also exhibit behavioral sensitization after repeated
exposures to an indirect dopamine agonist; however, the sensitized
responding appears to be weaker and less persistent than in adult rats (Kolta
et al., 1990; Smith & Morell, 2008). Similar to adults, the multi-trial sensitized
responding of preweanling rats is more robust when pretreatment and testing
occur in the same environmental context (Zavala et al., 2000). Unlike adults
however, preweanling rats exhibit robust context-independent behavioral
sensitization when using a one-trial paradigm (Kozanian et al., 2012). When
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these results are considered together, it appears that the characteristics of
behavioral sensitization (e.g. the strength and longevity of the sensitized
response, the role of associative processes, etc.) differ dramatically across
ontogeny.
In adult rats, the neural mechanisms underlying behavioral sensitization
differ depending on the psychostimulant being used. Previous studies have
shown that the selective D1-like receptor antagonist SCH 23390 blocks the
induction of amphetamine- and methamphetamine-, but not cocaine-induced
sensitization (Hamamura et al., 1991; Ujike et al., 1989). The only exception
was reported by Fontana et al. (1993), who demonstrated that SCH 23390
prevented the conditioned effects of cocaine-induced sensitization when using
a one-trial procedure. In terms of D2-like receptors, haloperidol blocks the
induction of methamphetamine- and cocaine-induced behavioral sensitization
in adult rats, while sulpiride is ineffective. Considering the inconsistent
findings, more research is needed to assess the importance of dopamine
receptors for the induction of behavioral sensitization.
In contrast to the large number of studies examining the induction of
psychostimulant-induced behavioral sensitization in adult rats and mice, the
role dopamine receptors play in the ontogeny of behavioral sensitization has
been largely ignored. In the only study to examine the importance of D1-like
receptors during early ontogeny, Mohd-Yusof et al. (2014) showed that SCH
23390 was unable to block methamphetamine- and cocaine-induced
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behavioral sensitization of young rats. These results indicate that the
mechanism mediating behavioral sensitization differ across ontogeny.
The purpose of this thesis was to assess the importance of D2-like
receptors for the induction of psychostimulant-induced behavioral sensitization
during early ontogeny. Rats were assessed during both the middle
(PND 13-17) and late (PND 17-21) preweanling periods because rats of these
ages often show different patterns of psychostimulant-induced behavioral
sensitization (Kozanian et al., 2012; McDougall et al., 2013). Likewise, both
methamphetamine and cocaine were tested, since adult rat sensitization
studies indicate that these two psychostimulants are differentially affected by
D2-like receptor blockade (Mattingly et al., 1994; Weiss et al., 1989).
The specific goals of this thesis were two-fold. First, to investigate the
importance of the D2-like receptor for cocaine- and
methamphetamine-induced one-trial behavioral sensitization during early
ontogeny. It was predicted that the D2-like antagonist raclopride would
prevent the induction of methamphetamine- and cocaine-induced behavioral
sensitization at PND 17 and PND 21. The basis for this prediction is that
raclopride prevents the induction of one-trial cocaine-induced sensitization in
adult rats (Fontana et al., 1993). The second goal of this thesis was to assess
the importance of the D2-like receptor for cocaine- and
methamphetamine-induced multi-trial behavioral sensitization during the
middle and late preweanling periods. It was predicted that raclopride would
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block both methamphetamine- and cocaine-induced multi-trial behavioral
sensitization at PND 17 and PND 21. Again, the basis for these predictions
are adult rat studies showing that raclopride and pimozide attenuate
sensitized responding when using multi-trial procedures (Beninger & Hahn,
1983; Beninger & Herz, 1986; Ushijima, Carino, & Horita, 1995).
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CHAPTER NINE:
MATERIALS AND METHODS
Subjects were young male and female rats of Sprague-Dawley descent
(Charles River, Hollister, CA) that were born and raised at California State
University, San Bernardino (CSUSB). Litters were culled to ten pups on
PND 3. All rats were housed on racks in large polycarbonate maternity cages
(56 × 34 × 22 cm) with wire lids and Tek-Fresh® bedding (Harlan,
Indianapolis, IN). Food and water was freely available. The colony room was
maintained at 22-23˚C, and kept under a 12L:12D cycle, with behavioral
testing occurring during the light phase of the cycle. Except during testing, rats
were kept with the dam and littermates. Testing was done in a separate
experimental room, maintained at 24-25˚C. Subjects were cared for according
to the “Guide for the Care and Use of Laboratory Animals” (National Research
Council, 2010) under a research protocol approved by the Institutional Animal
Care and Use Committee of CSUSB.
Apparatus
Behavioral testing was performed in commercially available (Coulbourn
Instruments, Allentown, PA, USA) activity monitoring chambers
(25 × 25 × 41 cm) housed in a testing room separate from the animal colony.
The activity chambers had acrylic walls, a gray plastic floor, and an open top.
Each chamber included an X-Y photobeam array, with 16 photocells and
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detectors, that was used to measure horizontal locomotor activity (distance
traveled). Photobeam resolution is 0.76 cm. The position of each rat was
determined every 100 ms (i.e., the sampling interval).
Drugs
(+)-Methamphetamine hydrochloride, ()-cocaine hydrochloride, and
S(-)-raclopride (+)-tartrate were dissolved in saline. Drugs were purchased
from Sigma-Aldrich (St. Louis, MO) and injected intraperitoneally (IP) at a
volume of 5 ml/kg.
Procedure
Experiment 1: Effects of D2 Receptor Blockade on
Cocaine-Induced One-Trial Behavioral Sensitization
One-trial cocaine-induced behavioral sensitization was assessed on
PND 20–21. On the pretreatment day, PND 20 rats were injected with
raclopride (0, 0.1, 0.5, 1, or 5 mg/kg) followed, 15 min later, by an injection of
30 mg/kg cocaine (see Figure 2). Rats in the acute control group were given
two injections of saline. After the second injection, rats were placed in activity
chambers and distance traveled was measured for 30 min. On the test day, all
rats were injected with 20 mg/kg cocaine and placed in activity chambers for
120 min.
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Group

PND 20

PND 21

Pretreatment Drugs

Test Day Drug

Control Group

Saline

Saline

Cocaine (20 mg/kg)

Sensitization Group

Saline

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Antagonist Group

0.1 mg/kg Raclopride

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Antagonist Group

0.5 mg/kg Raclopride

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Antagonist Group

1 mg/kg Raclopride

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Antagonist Group

5 mg/kg Raclopride

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Figure 2. Schematic Showing Drug Treatments for the Various Groups in
Experiment 1

Experiment 2: Effects of D2 Receptor Blockade on
Methamphetamine-Induced One-Trial Behavioral Sensitization
Since indirect dopamine agonists preferentially induce one-trial
sensitization at different ages (Kozanian et al., 2012), one-trial
methamphetamine-induced sensitization was assessed on PND 16-17. On the
pretreatment day, PND 16 rats were injected with raclopride (0, 0.1, 0.5, 1, or
5 mg/kg) followed, 15 min later, by an injection of 4 mg/kg methamphetamine
(see Figure 3). The acute control group was given two injections of saline.
After the second injection, locomotor activity was assessed for 30 min. On the
test day, all rats were injected with 2 mg/kg methamphetamine and locomotor
activity was assessed for 120 min. Doses of cocaine and methamphetamine
were based on previous studies using preweanling rats (Herbert et al., 2010;
McDougall et al., 2007, 2011; Kozanian et al., 2012).
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Group

PND 16

PND 17

Pretreatment Drugs

Test Day Drug

Control Group

Saline

Saline

METH (2 mg/kg)

Sensitization Group

Saline

METH (4 mg/kg)

METH (2 mg/kg)

Antagonist Group

0.1 mg/kg Raclopride

METH (4 mg/kg)

METH (2 mg/kg)

Antagonist Group

0.5 mg/kg Raclopride

METH (4 mg/kg)

METH (2 mg/kg)

Antagonist Group

1 mg/kg Raclopride

METH (4 mg/kg)

METH (2 mg/kg)

Antagonist Group

5 mg/kg Raclopride

METH (4 mg/kg)

METH (2 mg/kg)

Figure 3. Schematic Showing Drug Treatments for the Various Groups in
Experiment 2

Experiment 3a: Effects of D2 Receptor Blockade on CocaineInduced Multi-Trial Behavioral Sensitization During the Late
Preweanling Period
On PND 17-20, rats were injected with raclopride (0, 0.5, or 1 mg/kg)
followed, 15 min later, by an injection of 30 mg/kg cocaine (see Figure 4).
Rats in the acute control group were given two injections of saline. After the
second injection, rats were placed in activity chambers and distance traveled
was measured for 30 min. On PND 21, all rats were injected with 20 mg/kg
cocaine and placed in activity chambers for 120 min.
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Group

PND 17-20

PND 21

Pretreatment Drugs

Test Day Drug

Control Group

Saline

Saline

Cocaine (20 mg/kg)

Sensitization Group

Saline

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Antagonist Group

0.1 mg/kg Raclopride

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Antagonist Group

0.5 mg/kg Raclopride

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Antagonist Group

1 mg/kg Raclopride

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Figure 4. Schematic Showing Drug Treatments for the Various Groups in
Experiment 3a

Experiment 3b: Effects of D2 Receptor Blockade on
Methamphetamine-Induced Multi-Trial Behavioral Sensitization
During the Late Preweanling Period
To examine the effects of D2 receptor antagonism on
methamphetamine, separate groups of rats were treated as in Experiment 3a,
except that rats were pretreated with 4 mg/kg methamphetamine and tested
with 2 mg/kg methamphetamine (see Figure 5).

Group

PND 17-20

PND 21

Pretreatment Drugs

Test Day Drug

Control Group

Saline

Saline

METH (2 mg/kg)

Sensitization Group

Saline

METH (4 mg/kg)

METH (2 mg/kg)

Antagonist Group

0.1 mg/kg Raclopride

METH (4 mg/kg)

METH (2 mg/kg)

Antagonist Group

0.5 mg/kg Raclopride

METH (4 mg/kg)

METH (2 mg/kg)

Antagonist Group

1 mg/kg Raclopride

METH (4 mg/kg)

METH (2 mg/kg)

Figure 5. Schematic Showing Drug Treatments for the Various Groups in
Experiment 3b
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Experiment 4a: Effects of D2 Receptor Blockade on CocaineInduced Multi-Trial Behavioral Sensitization During the Middle
Preweanling Period
On PND 13-16, rats were injected with raclopride (0,0.5, or 1 mg/kg)
followed, 15 min later, by an injection of 30 mg/kg cocaine (see Figure 6).
Rats in the acute control group were given two injections of saline. After the
second injection, rats were placed in activity chambers and distance traveled
was measured for 30 min. On PND 17, all rats were injected with 20 mg/kg
cocaine and placed in activity chambers for 120 min.

Group

PND 13-16

PND 17

Pretreatment Drugs

Test Day Drug

Control Group

Saline

Saline

Cocaine (20 mg/kg)

Sensitization Group

Saline

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Antagonist Group

0.1 mg/kg Raclopride

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Antagonist Group

0.5 mg/kg Raclopride

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Antagonist Group

1 mg/kg Raclopride

Cocaine (30 mg/kg)

Cocaine (20 mg/kg)

Figure 6. Schematic Showing Drug Treatments for the Various Groups in
Experiment 4a

Experiment 4b: Effects of D2 Receptor Blockade on
Methamphetamine-Induced Multi-Trial Behavioral Sensitization
During the Middle Preweanling Period
To examine the effects of D2-like receptor antagonism on
methamphetamine during the middle preweanling period, separate groups of
rats were treated as in Experiment 4a, except that rats were pretreated with
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4 mg/kg methamphetamine and tested with 2 mg/kg methamphetamine (see
Figure 7).

Group

PND 13-16

PND 17

Pretreatment Drugs

Test Day Drug

Control Group

Saline

Saline

METH (2 mg/kg)

Sensitization Group

Saline

METH (4 mg/kg)

METH (2 mg/kg)

Antagonist Group

0.1 mg/kg Raclopride

METH (4 mg/kg)

METH (2 mg/kg)

Antagonist Group

0.5 mg/kg Raclopride

METH (4 mg/kg)

METH (2 mg/kg)

Antagonist Group

1 mg/kg Raclopride

METH (4 mg/kg)

METH (2 mg/kg)

Figure 7. Schematic Showing Drug Treatments for the Various Groups in
Experiment 4b

Data Analysis
For all experiments, omnibus repeated-measures analyses of variance
(ANOVAs) were used for statistical analysis of distance traveled data. More
specifically, pretreatment data for Experiments 1 and 2 were analyzed using
6 × 6 (Group × 5-min time block) mixed repeated measures ANOVAs, while
Experiments 3a, 3b, 4a, and 4b were analyzed using 5 × 4 × 6
(Group × Day × 5-min time block) mixed repeated measures ANOVAs. Test
day data for Experiments 1 and 2 were analyzed using 6 × 12
(condition × 10-min time block) repeated measures ANOVAs, whereas
Experiments 3a, 3b, 4a, and 4b were analyzed using 5 × 12
(condition × 10-min time block) mixed repeated measures ANOVAs. Post hoc
analysis of distance traveled data was done using Tukey tests (P < 0.05). The
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Huynh-Feldt epsilon statistic was used to adjust degrees of freedom (Huynh &
Feldt, 1976) when the assumption of sphericity was violated, as determined by
Mauchly’s test of sphericity. Corrected degrees of freedom was represented
by a superscripted “a” and rounded to the nearest whole number.
Litter effects were controlled through both experimental design and
statistical procedures. In most experiments, no more than one subject per
litter was assigned to a particular group. In cases where this procedure is not
possible (e.g., analysis of the pretreatment day), a single litter mean was
calculated from multiple littermates assigned to the same group (Holson &
Pearce 1992; Zorrilla, 1997). When possible, litter was used as the unit of
analysis for statistical purposes (Zorrilla, 1997). With this statistical model
each litter, rather than each rat, was treated as an independent observation
(i.e., a within analysis using one value/condition/litter).
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CHAPTER TEN:
RESULTS
Synopsis
In general, both cocaine and methamphetamine were able to induce
one-trial and multi-trial behavioral sensitization on PND 17 and PND 21 (see
Table 1). The only exception was that repeated methamphetamine treatment
did not cause multi-trial behavioral sensitization when testing occurred on
PND 21. The dopamine D2-like receptor antagonist raclopride had no effect
on cocaine- or methamphetamine-induced one-trial behavioral sensitization.
Furthermore, raclopride did not block the induction of cocaine-induced
multi-trial sensitization on PND 17 or PND 21. Interestingly, the D2-like
receptor antagonist was able to prevent the induction of multi-trial
methamphetamine sensitization when testing occurred on PND 17. Detailed
coverage of the various experimental results now follows.

Table 1. Summary of the Test Day Results for the Various Experiments

Experiment

Pretreatment
Age

Test
Age

Design

Agonist

Sensitization

1

PD 20

PD 21

One-Trial

Cocaine

Yes

No Effect

9

2

PD 16

PD 17

One-Trial Methamphetamine

Yes

No Effect

11

Yes

No Effect

13

Cocaine

Raclopride’s
Actions Figure

3a

PD 17-PD 20 PD 21

Multi-Trial

3b

PD 17-PD 20 PD 21

Multi-Trial Methamphetamine

No

No Effect

15

4a

PD 13-PD 16 PD 17

Multi-Trial

Yes

No Effect

17

4b

PD 13-PD 16 PD 17

Multi-Trial Methamphetamine

Yes

Blockade

19

Cocaine
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Experiment 1: Effects of D2 Receptor Blockade
on Cocaine-Induced One-Trial Behavioral
Sensitization
Pretreatment Day
When collapsed across the pretreatment day, rats pretreated with
cocaine alone or cocaine plus raclopride (0.1 or 0.5 mg/kg) had greater
distance traveled scores than saline controls [group main effect,
F(3, 18) = 7.99, p < 0.01] (see Figure 8A). The effect was not evident with the
two higher doses of raclopride (1 or 5 mg/kg) as locomotor activity was
reduced to the level of the saline controls. The effects of the D2 receptor
antagonist varied across the session, because rats treated with cocaine plus
raclopride (0.5, 1, or 5 mg/kg) had smaller distance traveled scores than the
cocaine-alone group on time blocks 1 and 2 [group × time block interaction,
F(13,88) = 3.41, p < 0.001; Tukey tests, p < 0.05] (see Figure 8B).
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Figure 8. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per group) on
the Pretreatment Day (PND 20). A. Mean Distance Traveled Scores Collapsed
Across Time Blocks 1-6. B. Mean Distance Traveled Scores on Time Blocks
1-6. Rats were Injected with Saline or 30 mg/kg Cocaine Immediately before a
30-min Placement in activity Chambers (Left Panel). In Addition, Separate
Group of Rats were Injected with Raclopride (0.1, 0.5, 1, or 5 mg/kg) 15 min
before Cocaine Treatment (Right Panel). a Significantly Different from the
Saline Control. b Significantly Different from the Cocaine Alone Group.
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Test Day
Cocaine-induced behavioral sensitization was evident in
nonraclopride-treated rats, because rats pretreated and tested with cocaine
had greater distance traveled scores than rats treated with only cocaine on the
test day (i.e., the acute control group; Figure 9) [group main effect,
F(5,35) = 3.83, p < 0.01, and Tukey tests, p < 0.05]. Interestingly, raclopride
(0.1, 0.5, 1, or 5 mg/kg) pretreatment did not reduce locomotor activity when
compared to rats treated with cocaine alone (i.e., raclopride did not block the
development of behavioral sensitization; see right panel Figure 9). Overall,
distance traveled scores showed a progressive decline across the testing
session, with the effect beginning on time block 3 [time main effect,
F(11,31) = 30.97, P < 0.001] (see Figure 9).

46

Test Day

A
Distance Traveled (cm)

100000
80000
a

a

0

0.1

60000
40000
20000
0
Acute
Control

1

5

Test Day

B
10000

Distance Traveled (cm)

0.5

Raclopride (mg/kg)

8000

10000

Cocaine + Raclopride

Cocaine (20 mg/kg)

0.1 mg/kg Raclopride
Acute Control

0.5 mg/kg Raclopride
1 mg/kg Raclopride

Cocaine Sensitization

6000

5 mg/kg Raclopride

8000
6000

4000

4000

2000

2000

0

0
1 2 3 4 5 6 7 8 9 10 11 12

1

2

3

4

5

6

7

8

9 10 11 12

10-Min Time Blocks

10-Min Time Blocks

Figure 9. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per Group) on the
Test Day (PND 21). A. Mean Distance Traveled Scores Collapsed across Time
Blocks 1-12. B. Mean Distance Traveled Scores on Time Blocks 1-12. Rats were
Challenged with Cocaine (20 mg/kg) Immediately before Behavioral Testing. On the
Pretreatment Day, Rats were Injected with Raclopride (0.1, 0.5, 1, or 5 mg/kg)
15 min before Cocaine Treatment (Right Panel). The Acute Control Group was
Injected with Saline on the Pretreatment Day and Injected with Cocaine on the Test
Day (Left Panel). Locomotor Activity was Assessed for 120 min. a Significantly
different from the Acute Control Group.
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Experiment 2: Effects of D2 Receptor Blockade on
Methamphetamine-Induced One-Trial
Behavioral Sensitization
Pretreatment Day
Rats injected with methamphetamine alone or methamphetamine plus
raclopride (0.1 or 0.5 mg/kg) had greater distance traveled scores than
saline-treated rats [group main effect, F(5,35) = 7.67, p < 0.001] (see Figure
10A). These effects varied across the testing session, because rats treated
with methamphetamine alone had significantly more locomotor activity on time
blocks 1 and 2 than saline controls [group × time block, F(25,175) = 6.22,
p < 0.001] (see Figure 10B; left panel). The three higher doses of raclopride
(0.5, 1, and 5 mg/kg) attenuated locomotor activity on time blocks 1, 2 and 4
when compared to the methamphetamine alone group (Tukey tests, p < 0.05)
(see Figure 10B; right panel).
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Figure 10. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per Group) on
the Pretreatment Day (PND 16). A. Mean Distance Traveled Scores Collapsed
across Time Blocks 1-6. B. Mean Distance Traveled Scores on Time Blocks 1-6.
Rats were Injected with Saline or 4 mg/kg Methamphetamine Immediately before a
30-min Placement in Activity Chambers (Left Panel). In addition, Separate Group of
Rats were Injected with Raclopride (0.1, 0.5, 1, or 5 mg/kg) 15 min before
Methamphetamine Treatment (Right Panel). a Significantly Different from the Saline
Control Group. b Significantly Different from the Methamphetamine Alone Group.
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Test Day
Overall, rats pretreated and tested with methamphetamine and rats
pretreated with 1 mg/kg raclopride had greater distance traveled scores than
the acute control group [group main effect, F(5,35) = 5.54, P < 0.001] (see left
panel, Figure 11). Rats pretreated and tested with methamphetamine had
greater distance travel scores than the acute control group on time blocks
3-11 [group × time block, F(55,385) = 2.68, p < 0.001]. Raclopride
pretreatment, regardless of dose, did not attenuate locomotor activity on the
test day (see Figure 11).
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Figure 11. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per Group) on
the Test Day (PND 17). A. Mean distance Traveled Scores Collapsed across Time
Blocks 1-12. B. Mean Distance Traveled Scores on Time Blocks 1-12. Rats were
Challenged with Methamphetamine (2 mg/kg) Immediately before Behavioral
Testing. On the Pretreatment Day, Rats were Injected with Raclopride (0.1, 0.5, 1,
or 5 mg/kg) 15 min before Methamphetamine Treatment (Right Panel). The Acute
Control Group was Injected with Saline on the Pretreatment Days and Injected with
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Methamphetamine on the Test Day (Left Panel). Locomotor was Assessed for
120 min. a Significantly different from the Acute Control Group

Experiment 3a: Effects of D2 Receptor Blockade on CocaineInduced Multi-Trial Behavioral Sensitization During the
Late Preweanling Period
Pretreatment Day
PND 17. Rats injected with cocaine alone or cocaine plus raclopride
(0.1 mg/kg) had greater distance traveled scores than rats treated with saline
or moderate to high doses of raclopride (0.5 and 1 mg/kg) [group main effect,
F(4,28) = 12.17, P < 0.001](see left top panel; Figure 12). Rats treated with
cocaine alone had greater distance traveled scores on time blocks 1-4 and 6
when compared to the saline group [group × time block interaction,
F(20,140) = 3.89, P < 0.001; Tukey tests, P < 0.05]. The effects of the D2
antagonist varied across the session, because rats treated with cocaine plus
raclopride (0.5 and 1 mg/kg) had smaller distance traveled scores than the
cocaine-alone group on time blocks 1 and 2 (Tukey tests, P < 0.05) (see left
top panel; Figure 12).
PND 18. Rats injected with cocaine alone or cocaine plus 0.1 mg/kg
raclopride had greater distance traveled scores than saline-treated rats [group
main effect, F(4,28) = 9.61, P < 0.001] (see right top panel; Figure 12). More
specifically, rats treated with cocaine alone had greater locomotor activity on
time blocks 1 and 2 than saline controls [group × time block interaction,
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F(20,140) = 5.11, P < 0.001; Tukey tests, P < 0.05]. Rats treated with 0.5 or
1 mg/kg raclopride had smaller distance traveled scores on time blocks 1 and
2 than the cocaine alone group (see right top panel; Figure 12).
PND 19. Rats injected with cocaine alone or cocaine plus a low dose of
raclopride (0.1 mg/kg) had greater distance traveled scores than
saline-treated rats [group main effect, F(4,28) = 12.21, P < 0.001] (see left
bottom panel; Figure 12). Moreover, rats treated with cocaine alone had
significantly greater locomotor activity on time blocks 1-4 than the saline
control group. Rats pretreated with raclopride (0.5 or 1 mg/kg) had smaller
distance traveled scores on time blocks 1-5 than the cocaine alone group
[group × time block interaction, F(20,140) = 7.17, P < 0.001; Tukey tests,
P < 0.05] (see left bottom panel; Figure 12).
PND 20. Rats injected with cocaine alone or cocaine plus 0.1 mg/kg
raclopride had greater distance traveled scores than saline-treated rats [group
main effect, F(4,28) = 7.16, P < 0.001] (see right bottom panel; Figure 12).
More specifically, rats treated with cocaine alone had greater locomotion on
time blocks 1 and 2 than saline controls, while rats treated with 1 mg/kg
raclopride had smaller distance traveled scores on time blocks 1 and 2 when
compared to the cocaine alone group [group × time block interaction,
F(20,140) = 3.76, P < 0.001; Tukey tests, P < 0.05] (see right bottom panel;
Figure 12). Starting on time block 3, locomotor activity decreased across time
[time main effect, F(5,35) = 41.74, P < 0.001].
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Figure 12. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per Group) on
the Four Pretreatment Days (PD 17, PD 18, PD 19, and PD 20). The Insets Show
Mean Distance Traveled Collapsed across the Conditioning Session. Rats were
Injected with Saline or 30 mg/kg Cocaine Immediately before a 30-min Placement
in Activity Chambers. In Addition, Separate Group of Rats were Injected with
Raclopride (0.1, 0.5, 1, or 5 mg/kg) 15 min before Cocaine Treatment. a
Significantly Different from the Saline Control Group. b Significantly different from
the Cocaine Alone Group.

Test Day
PND 21. Rats treated with cocaine alone had greater distance traveled
scores than the acute control group on the test day [group main effect,
F(4,28) = 6.37, P < 0.001] (see Figure 13). Raclopride pretreatment,
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regardless of dose, did not attenuate locomotor activity on the test day (see
Figure 13).
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Figure 13. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per group) on the
Test Day (PND 21). Rats were Challenged with Cocaine (20 mg/kg) Immediately
before Behavioral Testing. On the Pretreatment Day, Rats were Injected with
Raclopride (0.1, 0.5, 1, or 5 mg/kg) 15 min before Cocaine Treatment. The Acute
Control Group was Injected with Saline on the Pretreatment Days and Injected with
Cocaine on the Test Day. Locomotor Activity was Assessed for 120 min. The Right
Panel Shows Mean Distance Traveled Collapsed across the Testing Session.
a Significantly Different from the Acute Control Group.

Experiment 3b: Effects of D2 Receptor Blockade on
Methamphetamine-Induced Multi-Trial Behavioral
Sensitization During the Late Preweanling Period
Pretreatment Day
PND 17. Rats injected with methamphetamine-alone or
methamphetamine plus raclopride (0.1, 0.5, or 1 mg/kg) had greater distance
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traveled scores than the saline controls [group main effect, F(4,28) = 7.57,
P < 0.001](see top left panel; Figure 14). The effects of the D2 antagonist
varied across the session, because rats treated with methamphetamine alone
had greater distance traveled scores on time blocks 1-3 than saline controls
[group × time block interaction, F(20,140) = 3.89, P < 0.001; Tukey tests,
P < 0.05](see top left panel; Figure 14). Groups receiving methamphetamine
plus a moderate or high dose of raclopride (0.5 and 1 mg/kg) had smaller
distance traveled scores than the methamphetamine-alone group on time
blocks 1 and 2 (Tukey tests, P < 0.05).
PND 18. Rats injected with methamphetamine-alone or
methamphetamine plus raclopride (0.1 or 0.5 mg/kg) had greater distance
traveled scores than saline controls [group main effect, F(4,28) = 21.93,
P < 0.001] (see top right panel; Figure 14). More specifically, rats treated with
methamphetamine-alone had greater distance traveled scores on time blocks
1-6 when compared to saline controls [group × time block interaction,
F(20, 140) = 11.07, P < 0.001; Tukey tests, P < 0.05]. The three doses of
raclopride (0.1, 0.5, or 1 mg/kg) caused smaller distance traveled scores on
time blocks 1, 2, and 3 when compared to the methamphetamine-alone group
(Tukey tests, P < 0.05). In general, rats treated with raclopride (0.1, 0.5, or
1 mg/kg) exhibited increased locomotor activity as the session progressed
[time main effect, F(2,11) = 22.99, P < 0.001; Tukey tests, P < 0.05) (see top
right panel; Figure 14).
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PND 19. Rats injected with methamphetamine alone or
methamphetamine plus raclopride (0.1 or 0.5 mg/kg) had greater distance
traveled scores than the saline controls [group main effect, F(4,28) = 20.01,
P < 0.001] (see bottom left panel; Figure 14). More specifically, rats treated
with methamphetamine alone had greater distance traveled scores than saline
controls on time blocks 1-6 [group × time block interaction, F(20, 140) = 11.07,
P < 0.001; Tukey tests, P < 0.05]. The three doses of raclopride (0.1, 0.5, or
1 mg/kg) caused smaller distance traveled scores on time blocks 1 and 2
when compared to the methamphetamine-alone group, while 0.5 or 1 mg/kg
attenuated locomotor activity on time block 3 when compared to the
methamphetamine-alone group (Tukey tests, P < 0.05) (see bottom left panel;
Figure 14).
PND 20. Rats treated with methamphetamine alone or
methamphetamine plus raclopride (0.1 or 0.5 mg/kg) had greater distance
traveled scores were compared to saline controls, F(4,28) = 19.99, P < 0.001]
(see bottom right panel; Figure 14). Rats treated with methamphetamine
alone had greater distance traveled scores than saline controls on time blocks
1-6, while raclopride (0.1, 0.5, and 1 mg/kg) attenuated locomotor activity on
time blocks 1 and 2 when compared to the methamphetamine alone group.
Raclopride (0.5 and 1 mg/kg) reduced locomotor activity on time block 3
relative to the methamphetamine-alone group [group × time block interaction,
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F(20, 140) = 9.04, P < 0.001; Tukey tests, P < 0.05](see bottom right panel;
Figure 14).
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Figure 14. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per Group) on
the Four Pretreatment Days (PND 17, PND 18, PND 19, and PND 20). The Insets
Show Mean Distance Traveled Collapsed across the Conditioning Session. Rats
were Injected with Saline or 4 mg/kg Methamphetamine Immediately before a
30-min Placement in Activity Chambers. In Addition, Separate Group of Rats were
Injected with Raclopride (0.1, 0.5, 1, or 5 mg/kg) 15 min before Cocaine Treatment.
a Significantly Different from the Saline Control Group. b Significantly Different from
the Methamphetamine Alone Group.
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Test Day
PND 21. Rats pretreated with methamphetamine did not differ from the
acute control group on the test day. Raclopride pretreatment, regardless of
dose, did not attenuate locomotor activity on the test day (see right panel;
Figure 15).
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Figure 15. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per Group) on
the Test Day (PND 21). Rats were Challenged with Methamphetamine (2 mg/kg)
Immediately before Behavioral Testing. On the Pretreatment Days, Rats were
Injected with Raclopride (0.1, 0.5, 1, or 5 mg/kg) 15 min before Methamphetamine
Treatment. The Acute Control Group was Injected with Saline on the Pretreatment
Days and Injected with Methamphetamine on the Test Day. Locomotor Activity was
Assessed for 120 min. The Right Panel Shows Mean Distance Traveled Collapsed
across the Testing Session.
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Experiment 4a: Effects of D2 Receptor Blockade on CocaineInduced Multi-Trial Behavioral Sensitization During the
Middle Preweanling Period.
Pretreatment Day
PND 13. Rats injected with cocaine alone or cocaine plus 0.5 mg/kg
raclopride had greater distance traveled scores than saline-treated rats [group
main effect, F(1,10) = 6.54, P < 0.05] (see top left panel; Figure 16). Overall,
rats treated with cocaine-alone had greater distance traveled scores on time
blocks 1-3 and 5-6 than saline controls [group × time block interaction,
F(20, 140) = 2.62, P < 0.001; Tukey tests, P < 0.05]. Rats treated with
raclopride (0.1, 0.5, or 1 mg/kg) exhibited less locomotor activity on time
blocks 1 and 6 than the cocaine alone group (Tukey tests, P < 0.05) (see top
left panel; Figure 16).
PND 14. When collapsed across the pretreatment day, rats pretreated
with cocaine alone or cocaine plus raclopride (0.1 or 0.5 mg/kg) had greater
distance traveled scores than saline treated rats [group main effect,
F(2,14) = 12.30, P < 0.001] (see top right panel inset; Figure 16). Rats treated
with cocaine alone had greater locomotor activity than saline controls on time
blocks 1, 2, 4, 5, and 6, while raclopride (0.5 or 1 mg/kg) treated rats exhibited
less locomotor activity than the cocaine-alone group on time blocks 1 and 2
[group × time block interaction, F(20, 140) = 2.36, P < 0.001; Tukey tests,
P < 0.05] (see top right panel; Figure 16).
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PND 15. Overall, rats injected with cocaine alone had greater distance
traveled scores than rats treated with saline [group main effect,
F(4,28) = 4.69, P < 0.05] (see bottom left panel inset; Figure 16). This effect
varied across the testing session, because rats treated with cocaine alone had
greater distance traveled scores on time blocks 1 and 2 than saline controls;
the group given cocaine plus 1 mg/kg raclopride exhibited significantly less
locomotor activity on time blocks 1 and 2 than the cocaine alone group [group
× time block interaction, F(20, 140) = 3.30, P < 0.001; Tukey tests, P < 0.05]
(see bottom left panel; Figure 16).
PND 16. Rats injected with cocaine alone or cocaine plus 0.1 mg/kg
raclopride had greater distance traveled scores than rats treated with higher
doses of raclopride (0.5 and 1 mg/kg) [group main effect, F(2,17) = 9.72,
P < 0.001]. Rats treated with cocaine alone exhibited greater locomotor
activity on time blocks 1 and 2 than saline controls, while rats treated with
1 mg/kg raclopride had significantly less locomotion than the cocaine alone
group on time blocks 1 and 2 [group × time block interaction,
F(20, 140) = 5.98, P < 0.001; Tukey tests, P < 0.05] (see bottom right panel
inset; Figure 16). Overall, locomotor activity decreased across the first three
time blocks for all groups [time main effect, F(2,16) = 12.94, P < 0.001] (see
bottom right panel; Figure 16).
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Figure 16. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per Group) on
the Four Pretreatment Days (PND 13, PND 14, PND 15, and PND 16). The Insets
Show Mean Distance Traveled Collapsed across the Conditioning Session. Rats
were Injected with Saline or 30 mg/kg Cocaine Immediately before a 30-min
Placement in Activity Chambers. In Addition, Separate Group of Rats were Injected
with Raclopride (0.1, 0.5, 1, or 5 mg/kg) 15 min before Cocaine Treatment.
a Significantly Different from the Saline Control Group. b Significantly Different from
the Cocaine Alone Group.

Test Day
PND 17. Rats pretreated and tested with cocaine had greater distance
traveled scores than the acute control group [group main effect,
F(4,28) = 8.30, P < 0.001] (see right panel; Figure 17). Moreover, rats
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challenged with cocaine had greater locomotor activity than the acute control
group on time blocks 1, 10, 11, and 12 [group × time block interaction,
F(44, 308) = 5.43, P < 0.001; Tukey tests, P < 0.05]. Raclopride pretreatment,
regardless of dose, did not attenuate locomotor activity on the test day.
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Figure 17. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per Group) on
the Test Day (PND 17). Rats were Challenged with Cocaine (20 mg/kg)
Immediately before Behavioral Testing. On the Pretreatment Days, Rats were
Injected with Raclopride (0.1, 0.5, 1, or 5 mg/kg) 15 min before Cocaine Treatment.
The Acute Control Group was Injected with Saline on the Pretreatment Days and
Injected with Cocaine on the Test Day. Locomotor Activity was Assessed for
120 min. The Right Panel Shows Mean Distance Traveled Collapsed across the
Testing Session. a Significantly Different from the Acute Control Group.
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Experiment 4b: Effects of D2 Receptor Blockade on
Methamphetamine-Induced Multi-Trial Behavioral
Sensitization During the Middle
Preweanling Period
Pretreatment Day
PND 13. Rats injected with methamphetamine alone or
methamphetamine plus raclopride (0.1, 0.5, or 1 mg/kg) had greater distance
traveled scores than saline controls [group main effect, F(4,28) = 9.47,
P < 0.001](see top left panel inset; Figure 18). Moreover, rats treated with
cocaine alone exhibited greater locomotor activity on time blocks 1-3 than
saline controls, while rats pretreated with raclopride (0.1, 0.5, or 1 mg/kg) had
smaller distance traveled scores on time block 1 than the
methamphetamine-alone group [group × time block interaction,
F(20, 140) = 6.60, P < 0.001; Tukey tests, p < 0.001] (see top left panel;
Figure 18).
PND 14. Rats injected with methamphetamine-alone or
methamphetamine plus raclopride (0.1, 0.5, or 1 mg/kg) had greater distance
traveled scores when compared to the saline controls [group main effect,
F(4,28) = 19.66, P < 0.001] (see top right panel inset; Figure 18). Moreover,
rats treated with cocaine alone showed greater locomotion on time blocks 2-5
than saline controls [group × time block interaction, F(20, 140) = 17.33,
P < 0.05; Tukey tests, p < 0.001] (see top right panel; Figure 18). Rats
pretreated with 1 mg/kg raclopride had smaller distance traveled scores on
time block 1, 2, and 3 (Tukey tests, P < 0.05).

64

PND 15. Rats injected with methamphetamine alone or
methamphetamine plus raclopride (0.1, 0.5, or 1 mg/kg) had greater distance
traveled scores than saline controls [group main effect, F(4,28) = 26.13,
P < 0.001] (see bottom left panel inset; Figure 18). More specifically, rats
treated with methamphetamine alone had greater locomotor activity on time
blocks 1 and 2 than saline controls [group × time block interaction,
F(20, 140) = 41.54, P < 0.001; Tukey tests, P < 0.05]. Rats pretreated with
raclopride (1 mg/kg) had smaller distance traveled scores on time block 1 and
2 when compared to the methamphetamine alone group (see bottom left
panel; Figure 18).
PND 16. Rats injected with methamphetamine alone or
methamphetamine plus raclopride (0.1, 0.5, or 1 mg/kg) had greater distance
traveled scores than the saline controls [group main effect, F(4,28) = 26.82,
P < 0.001] (see bottom right panel inset; Figure 18). Moreover, rats treated
with methamphetamine alone exhibited greater locomotion than saline
controls on time blocks 1 and 2 [group × time block interaction,
F(20, 140) = 17.33, P < 0.001; Tukey tests, p < 0.05]. Rats pretreated with
raclopride (1 mg/kg) had smaller distance traveled scores on time blocks 1
and 2 when compared to the methamphetamine-alone group, but they had
greater distance traveled scores than the saline group later in the testing
session (Tukey tests, P < 0.05) (see bottom right panel; Figure 18).
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Figure 18. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per Group) on
the Four Pretreatment Days (PND 13, PND 14, PND 15, and PND 16). The Insets
Show Mean Distance Traveled Collapsed across the Conditioning Session. Rats
were Injected with Saline or 4 mg/kg Methamphetamine Immediately before a
30-min Placement in Activity Chambers. In Addition, Separate Group of Rats were
Injected with Raclopride (0.1, 0.5, 1, or 5 mg/kg) 15 min before Methamphetamine
Treatment. a Significantly Different from the Saline Control Group. b Significantly
Different from the Methamphetamine Alone Group.

Test Day
PND 17. Overall, rats pretreated and tested with methamphetamine
had greater distance traveled scores than the acute control group, while
pretreatment with (0.5 or 1 mg/kg) raclopride attenuated locomotor activity on
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the test day [group main effect, F(4,28) = 18.24, P < 0.001] (see right panel,
Figure 19). Furthermore, rats pretreated and tested with methamphetamine
exhibited greater locomotion on time blocks 2-12 than the acute control group
(see left panel Figure 19). Raclopride pretreated rats had smaller locomotor
activity scores than the methamphetamine alone group (i.e. the sensitized
group) on time blocks 6-9 [group × time block interaction, F(44, 308) = 5.43,
P < 0.001; Tukey tests, p < 0.05].
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Figure 19. Mean Distance Traveled Scores (±SEM) of Rats (n = 8 per Group) on
the Test Day (PND 17). Rats were Challenged with Methamphetamine (2 mg/kg)
Immediately before Behavioral Testing. On the Pretreatment Days, Rats were
Injected with Raclopride (0.1, 0.5, 1, or 5 mg/kg) 15 min before Methamphetamine
Treatment. The Acute Control Group was Injected with Saline on the Pretreatment
Days and Injected with Methamphetamine on the Test Day. Locomotor Activity was
Assessed for 120 min. Right Panel Show Mean Distance Traveled Collapsed
Across the Testing Session. a Significantly Different from the Acute Control Group.
b Significantly Different from the Methamphetamine Alone Group.
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CHAPTER ELEVEN:
DISCUSSION
Summary of Results and Hypotheses
The purpose of this thesis was to investigate the importance of D2-like
receptors for the induction of psychostimulant-induced behavioral sensitization
during early ontogeny. More specifically, the goals of this thesis were to
determine the role of D2-like receptors for cocaine- and
methamphetamine-induced one-trial and multi-trial behavioral sensitization
during the preweanling period. It was predicted that the D2-like receptor
antagonist raclopride would prevent the induction of one-trial
methamphetamine- and cocaine-induced behavioral sensitization at PND 17
and PND 21, respectively. Furthermore, it was predicted that raclopride would
block both methamphetamine- and cocaine-induced multi-trial behavioral
sensitization at PND 17 and PND 21.
Contrary to predictions, the D2-like receptor antagonist raclopride did
not attenuate cocaine-induced sensitized responding on PND 21 when a
one-trial procedure was employed. Furthermore, raclopride did not prevent the
induction of methamphetamine-induced one-trial behavioral sensitization on
PND 17. In regards to cocaine-induced multi-trial behavioral sensitization,
sensitized responding was evident on both PND 17 and PND 21. However,
the D2-like antagonist raclopride, regardless of dose, was unable to block the
induction of cocaine-induced behavioral sensitization when assessed on the
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test day. In contrast to all of the previously mentioned results, higher doses of
raclopride (0.5 and 1 mg/kg) blocked the induction of
methamphetamine-induced sensitization on PND 17. Methamphetamine did
not produce behavioral sensitization during the late preweanling period (i.e. on
PND 21), nor did raclopride inhibit methamphetamine-induced locomotor
activity on PND 21.
Comparing the Present Results to Adult Studies
Multi-trial Behavioral Sensitization
Dopamine D2-like receptor antagonists attenuate multi-trial
methamphetamine-induced behavioral sensitization in adult rats (Kuribara,
1994). A similar effect was observed in the present study since raclopride (0.5
and 1 mg/kg) attenuated the multi-trial sensitized responding of preweanling
rats. The ability of raclopride to block behavioral sensitization is consistent
with results using other reward-related paradigms, such as sucrose intake and
conditioned place preference (Mizoguchi, Yamada, Mizuno, Mizuno Nitta,
Noda, & Nabeshima, 2004; Tyrka, Gayle, & Smith, 1992). The ability of
raclopride to block the induction of one-trial methamphetamine-induced
behavioral sensitization in adult rats has not been assessed, so ontogenetic
comparisons cannot be made.
According to some earlier studies using adult rodents, dopamine
D2-like receptor antagonists prevent the induction of multi-trial
cocaine-induced behavioral sensitization (Mattingly et al., 1996). Based on
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these studies, it was predicted that raclopride would also attenuate the
multi-trial cocaine-induced sensitized responding of preweanling rats;
however, these results were not obtained. Despite using a broad dose range
of raclopride (0.1-5 mg/kg), the dopamine D2-like receptor antagonist did not
attenuate the cocaine-induced sensitized responding of preweanling rats. This
finding implies that dopamine receptors are not involved in the induction of
multi-trial cocaine-induced behavioral sensitization during the preweanling
period. Whether these results represent a true ontogenetic difference is
uncertain, since White et al. (1998) reported that the D2 receptor antagonist
eticlopride failed to prevent the induction of multi-trial cocaine-induced
sensitization in adult rats. These authors suggest that earlier studies showing
D2 receptor involvement in the multi-trial behavioral sensitization of adult rats
were confounded due to the use of an excessive dose of haloperidol causing
nonspecific behavioral effects (Mattingly et al., 1996; White et al., 1998).
One-trial Behavioral Sensitization
Despite these contradictory findings involving multi-trial behavioral
sensitization, it does appear that D2 receptor antagonists prevent the
induction of one-trial behavioral sensitization in adult rats (Fontana et al.,
1993; Weiss et al., 1989). In contrast, dopamine antagonists do not block the
one-trial behavioral sensitization of preweanling rats (present study;
Mohd-Yusof et al., 2014). This age-dependent difference may be due to
environmental conditioning factors. In adult rats and mice, one-trial behavioral
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sensitization is exclusively context-dependent, while multi-trial sensitization is
not (Anagnostaras et al., 2002; Battisti et al., 1999; Drew & Glick, 1989). If the
role of dopamine receptors is to mediate the contextual conditioning aspects
of behavioral sensitization, then only the one-trial behavioral sensitization of
adult rats should be sensitive to dopamine receptor blockade. Consistent with
this suggestion, D1-like and D2-like receptor antagonists only prevent the
induction of one-trial and not multi-trial cocaine sensitization in adult rats
(White et al., 1998). Since the one-trial behavioral sensitization of preweanling
rats is context-independent (Kozanian et al., 2012), then dopamine
antagonists should not be effective at blocking induction. Consistent with this
idea, raclopride did not block the cocaine-induced one-trial behavioral
sensitization of preweanling rats.
Role of Non-Dopaminergic Receptor Systems
When considered together, results from adult and preweanling rat
studies suggest that dopamine receptors either play no role or only a minor
role in the induction of psychostimulant-induced behavioral sensitization. This
begs the question as to which neurotransmitter systems are responsible for
mediating the induction of behavioral sensitization. Cocaine and
methamphetamine do not exclusively affect dopamine neurons. For example,
cocaine increases serotonin and norepinephrine levels (Seiden et al., 1993),
while amphetamine- and methamphetamine-like compounds increase
norepinephrine levels as well as dopamine (Ritz et al., 1987; Seiden et al.,
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1993). This lack of specificity leaves open the possibility that cocaine and
methamphetamine may also affect behavioral sensitization by modulating
serotonergic and/or noradrenergic processes.
Consistent with this idea, previous studies have shown that serotonin
5-HT2 antagonists, such as ritanserin, partially block the induction of
methamphetamine sensitization (Tanaka, Ishigooka, Watanabe, Nagata, &
Miura, 1998). Cocaine sensitization is also inhibited by the serotonin 5-HT3
antagonist ondansetron (King, Xiong, & Ellinwood, 1997). The adrenergic
system may also mediate the induction of behavioral sensitization. In fact,
Auclair et al. (2004) states that the induction of psychostimulant-induced
behavioral sensitization is exclusively mediated by 5-HT2A and α-1B adrenergic
receptors. Thus, the inability of raclopride to block the one-trial behavioral
sensitization of young rats may indicate that non-dopaminergic systems
mediate the induction process during the preweanling period.
Comparing One-Trial and Multi-Trial Behavioral
Sensitization in Preweanling Rats
According to Valjent and colleagues (2010), a single exposure protocol
provides a simple paradigm that can measure the induction of behavioral
sensitization, while avoiding the problems of tolerance and dependence.
These authors also suggest that the neural mechanisms mediating one-trial
and multi-trial methamphetamine-induced behavioral sensitization differ
(Valjent et al., 2010). In the present study, a dopamine D2-like antagonist was
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unable to block one-trial methamphetamine-induced behavioral sensitization
on PND 17. In contrast, repeated treatment with high doses of raclopride (0.5
and 1 mg/kg) attenuated the induction of multi-trial
methamphetamine-induced behavioral sensitization on PND 17.
Several explanations may account for the different pattern of results
provided by the one- and multi-trial procedures. One possibility is that the
underlying neural mechanisms mediating one-trial and multi-trial sensitization
differ. Alternatively, it is possible that repeatedly exposing rats to dopamine
antagonists may cause nonspecific neural changes (i.e., changes unrelated to
modifying the acute effects of psychostimulant drugs) that weaken the
sensitized response. Thus, the impaired sensitized responding that is evident
when using a multi-trial procedure may be an artifact of repeated antagonist
administration (Mohd-Yusof et al., 2014). Finally, the multi-trial behavioral
sensitization of preweanling rats is context-dependent (Wood et al., 1998;
Zavala et al., 2000), while one-trial behavioral sensitization is
context-independent (Kozanian et al., 2012). This dichotomy leaves open the
possibility that D2-like receptor antagonism was interfering with contextual
conditioning and, thus, only multi-trial behavioral sensitization should be
disrupted by D2 receptor antagonism.
Ontogeny of Dopamine Receptors
Past studies have shown that the dopamine system exhibits
age-dependent changes across postnatal development. For example, firing
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rates of neurons in the nigrostriatal pathway increase gradually with age (Pitts
& Chiodo, 1990). Furthermore, the number of D1-like receptors gradually
increases until approximately the onset of puberty (PND 40), when dopamine
receptors are over-expressed. The number of D1-like and D2-like receptors
then declines (i.e. pruning) to levels that are maintained throughout adulthood
(Andersen et al., 2000). These changes in synaptic plasticity during
development, when coupled with early drug exposure, could possibly explain
the age-dependent differences in pharmacological sensitivity to
psychostimulants.
Effects of Raclopride During the Pretreatment Phase
Data collected on the pretreatment days are also informative. When
rats were given raclopride (0.1-1 mg/kg) during the pretreatment phase (oneor multi-trial), the D2-like antagonist was unable to block the acute locomotor
activating effects of methamphetamine and cocaine. Importantly, the ability or
inability of raclopride to block agonist-induced effects on the pretreatment day
did not determine whether a sensitized response was expressed on the test
day. For example, raclopride attenuated the acute effects of cocaine during
the pretreatment phase; however, raclopride did not prevent sensitization from
being expressed on the test day (see Fig. 16). In contrast, raclopride (0.1 and
0.5 mg/kg) actually potentiated methamphetamine-induced locomotion by the
end of the pretreatment phase. Even so, the sensitized response was reduced
on the test day (see Fig. 18).
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Other lines of research also suggest that the occurrence or
non-occurrence of agonist-induced locomotor activity on the pretreatment day
does not determine whether a sensitized response will be evident on the test
day. For example, preweanling and adult rats anesthetized during the
pretreatment phase (i.e., no locomotor activity was possible) exhibited
behavioral sensitization on the test day (Herbert et al., 2010; Wang & Hsiao,
2003), while adult mice injected with a D2-like antagonist up to 5 hours after
methamphetamine pretreatment (i.e., A full locomotor response was evident
on the pretreatment day) did not exhibit behavioral sensitization (Kuribara,
1995). Therefore, the induction of behavioral sensitization is independent of
the overt manifestation of drug-induced locomotor activity during the
pretreatment phase.
Summary
In summary, both cocaine and methamphetamine were able to produce
behavioral sensitization when a one-trial or a multi-trial procedure was used.
The dopamine D2-like antagonist raclopride failed to prevent the induction of
one-trial cocaine- and methamphetamine-induced behavioral sensitization,
thus D2-like receptor stimulation is unnecessary when a one-trial procedure is
used. The ability of raclopride to prevent the induction of multi-trial
methamphetamine-induced sensitization suggests that the neural
mechanisms underlying behavioral sensitization in young rats differs
depending on the type of paradigm being employed. Lastly, age-dependent
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differences in the importance of contextual conditioning may explain why
D1-like and D2-like receptor antagonists prevent the induction of one-trial
behavioral sensitization in adult rats, but not rat pups (see also Mohd-Yusof et
al., 2014).
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